4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)
$8.85 0.14 (1.6073%)
Analysed 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) News Sources
electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?
10-04-2026
yahoo.com
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
07-05-2026
yahoo.com
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
07-05-2026
yahoo.com
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
07-05-2026
yahoo.com
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
11-05-2026
yahoo.com
4DMT Announces New Employment Inducement Grants
15-05-2026
yahoo.com
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
17-05-2026
marketbeat.com
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You?
20-05-2026
yahoo.com
4DMT to Participate in Upcoming Investor Conferences
27-05-2026
yahoo.com
Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight
27-05-2026
yahoo.com
What is the current price of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)?
The current price of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) is $8.85.
4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) absolute price change since previous trading day?
The absolute price change of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) since the previous trading day is $0.14.
4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) percentage price change since previous trading day?
The percentage price change of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) since the previous trading day is 1.6073%.
What is the most recent average sentiment score for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)?
The most recent average sentiment score for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) is 67 out of 100.
What is the most recent average sentiment for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)?
The most recent sentiment for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) is .
SEC-8K** Filing Available For 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.